[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"parkinsons-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:parkinsons-disease":607},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,108,0,25,[9,49,86,111,133,158,183,211,230,252,273,296,308,333,360,381,402,424,452,469,489,511,537,558,583],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100053447",false,"NCT07330258","A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite Taking Parkinson's Medications","A Natural History Study of Treated Parkinson's Disease Patients Experiencing Motor Complications","Inclusion Criteria for Patient:\n\n* Individual of any sex ≥45 to ≤75 years of age at informed consent (at least 30% ≤60 years of age).\n* Diagnosis of clinically established Parkinson's disease (PD) as defined by the Movement Disorder Society (MDS) Clinical Diagnostic Criteria for PD ≥4 and \\\u003C12 years from time of PD diagnosis at informed consent.\n* Modified H\\&Y stage II-III in the practically defined OFF-medication state (≥12 hours from last dose of antiparkinsonian medications).\n* Score of ≥30 on MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III in the OFF-medication state.\n* Presence of motor fluctuations with ≥1 hour of absolute time in the OFF state per day as assessed by clinician\u002Fpatient at screening.\n* Receiving stable antiparkinsonian medication regimen for ≥4 weeks prior to screening with a levodopa daily dose ≥300 mg or a dosing frequency of ≥3 times per day.\n* Responsiveness to levodopa as determined by change in the following measures from the practically defined OFF state to ON state after taking typical first-daily dose of PD-medications: i. any degree of improvement (≥0.5 point) in modified H\\&Y stage OR. ii. ≥30% improvement in MDS-UPDRS part III score.\n* Montreal Cognitive Assessment (MoCA) score of ≥24.\n* Agree to participate and provide signed informed consent.\n\nExclusion Criteria for Patient:\n\n* Known history or presence of conditions that may provide an alternative to a PD diagnosis including but not limited to: multiple system atrophy, progressive supranuclear palsy, striatonigral degeneration, corticobasal syndrome\u002Fdegeneration, vascular Parkinsonism, drug-induced Parkinsonism, essential tremor, diffuse Lewy body disease, Lewy body dementia, Huntington's disease, Wilson's disease, Fahr's disease, Alzheimer's disease, cerebrovascular disease, brain tumor, trauma, and infection.\n* Known history or presence of significant vascular and\u002For cardiovascular disease limited to: stroke, transient ischemic attacks, poorly controlled hypertension, poorly controlled diabetes, unstable angina pectoris, or unstable myocardial infarction.\n* Known history or presence of significant psychosis or impulse control disorder, or untreated or sub optimally treated depression.\n* Known history or presence of human immunodeficiency virus, hepatitis B virus, hepatitis C virus, syphilis, or tuberculosis.\n* Current or previously active malignant disease within the past 5 years, except definitively treated cutaneous squamous cell carcinoma, basal cell carcinoma, or in situ uterine cervical carcinoma.\n* Currently pregnant, nursing, lactating, breastfeeding, or plan to be during study duration.\n* Known history or current use of percutaneous levodopa\u002Fcarbidopa intestinal gel, subcutaneous levodopa, or apomorphine pump.\n* Prior history of brain surgery, including but not limited to: deep brain stimulation (DBS), pallidotomy, focused ultrasound thalamotomy, or other experimental neurosurgical procedure.\n* Known history or current participation in cell or gene therapy procedures.\n* Current participation in any interventional clinical trial.\n\nInclusion Criteria for Care Partner:\n\n* ≥18 years of age at informed consent.\n* Identified by the PD patient as their primary care partner.\n* Agree to participate and the ability to provide signed informed consent independently, without the need for a legal representative.\n\nExclusion Criteria for Care Partner:\n\n* Not applicable.","ALL","45 Years","75 Years",{"count":20,"type":21},300,"ESTIMATED","OBSERVATIONAL","This is an observational study in which data are collected and studied from Parkinson's disease patients who have movement symptoms despite taking standard Parkinson's medications. In observational studies, observations are made without any changes to the participant's healthcare or treatment plan. No investigational product will be administered in this study, as participants will be treated with the standard of care that medical experts currently consider most appropriate.\n\nParkinson's disease (PD) is a condition that affects the brain and causes problems with movement and other body functions. The symptoms of Parkinson's disease can worsen over time. People with Parkinson's disease may experience shaking (tremor), slow movements, stiff muscles, trouble walking, and problems with balance. They can also have other symptoms, such as difficulty thinking clearly, changes in mood, or difficulty sleeping. Parkinson's disease mostly affects older adults, but it can happen to younger people too. There is no cure, but treatments can help manage the symptoms and improve quality of life.\n\nWhile doctors and researchers know that Parkinson's disease affects people in different ways and can worsen over time, there are still many things they don't fully understand-especially for people who experience movement symptoms despite taking their usual Parkinson's medicines. Earlier studies did not follow these patients long enough or collect all the important information needed. This study is being done to fill those gaps.\n\nThe main purpose of this study is to better understand how Parkinson's disease changes over time in patients who experience movement symptoms while taking standard oral Parkinson's medications, what challenges patients and their care partners face, and how their treatments are working in real life. To do this, researchers will collect data on:\n\n* Sociodemographics (e.g. age, gender, race\u002Fethnicity, insurance provider).\n* Medical history and vital signs (e.g. comorbidities, family history of Parkinson's, height, weight, blood pressure).\n* Medications and treatments (e.g. Parkinson's and non-Parkinson's medications and other treatments, rehabilitation therapy sessions, use of mobility assistance devices).\n* Movement symptoms (e.g. tremor, slow movement, balance).\n* Non-movement symptoms (e.g. cognition, mood, sleep, activities of daily living).\n* Molecular data (e.g. genetics, α-synuclein).\n* Burden of care (e.g. economic cost).\n\nData will come from questionnaires or rating scales conducted by the doctor with the patient during study visits, diaries and logs completed by the patient, medical records, health insurance claims records, blood samples and skin biopsies, a digital device that records movement\u002Fnon-movement symptoms, and questionnaires completed by the care partner.\n\nData will be collected from December 2025 to December 2032. Each participant may be followed for up to 5 years.",[25],"Parkinson's Disease",[27,28,29,30,31,32,33,34,35],"Natural history study","Parkinson's disease","PD Motor (Hauser) Diary","MDS-UPDRS","Electronic health\u002Fmedical records","Administrative claims data","Biological samples","Digital health technology","Care partner","RECRUITING","2026-07-10",{"date":39,"type":40},"2026-07-13","ACTUAL",{"date":42,"type":21},"2026-07-22",{"date":44,"type":21},"2033-06-01",{"name":46,"class":47},"Bayer","INDUSTRY",26,{"id":50,"slug":4,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":16,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":69,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":85},"100392965","NCT04396873","PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease","Phase 1 Study: PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease","* INCLUSION CRITERIA:\n\nPatients: In order to be eligible to participate in this study, patients must meet all of the following criteria:\n\n1. Aged 18 or older.\n2. Be able (or have their Legally Authorized Representative (LAR) be able) to understand the study and be willing to sign a written informed consent document.\n3. Have been diagnosed by a neurologist or psychiatrist with MCI, ALS, PD, or an adult onset neurodegenerative dementia, such as AD (including amyloid negative subjects), FTD, corticobasal syndrome, or Huntington s disease.\n4. Be in good general health as evidenced by medical history and physical examination.\n5. Have their radial artery pulse checked for the presence of adequate ulnar collateral flow and the absence of any metal or foreign objects in both wrists.\n6. Agree to adhere to the lifestyle considerations.\n\nHealthy volunteers: In order to be eligible to participate in this study, healthy volunteer subjects must meet all of the following criteria:\n\n1. Aged 18 or older.\n2. Female participants of childbearing potential must be using a medically acceptable means of contraception\n3. Able provide informed consent.\n4. Be in good general health, as evidenced by medical history and physical examination, and have no cognitive impairment.\n5. Be enrolled in 01-M-0254, The Evaluation of Participants with Mood and Anxiety Disorders and Healthy Volunteers or 17-M-0181, Recruitment and Characterization of Healthy Research Volunteers for NIMH Intramural Studies\n6. Have their radial artery pulse checked for the presence of adequate ulnar collateral flow and the absence of any metal or foreign objects in both wrists.\n7. Agree to adhere to the lifestyle considerations.\n\nEXCLUSION CRITERIA:\n\nBoth patients and healthy volunteers who meet any of the following criteria will be excluded from participation in this study:\n\n1. Clinically significant abnormalities on EKG or laboratory testing. This includes CBC and acute care panel (Na, K, Cl, CO2, creatinine, glucose, urea nitrogen). Any lab value that is two-times the upper limit or even lower values in the investigator s judgment. Creatinine level \\>1.3 mg\u002FdL\n2. Subjects should not have taken Non-Steroidal Anti-Inflammatory Drugs (NSAID) for two weeks prior to the PET scan. Aspirin, corticosteroids (with the exception of skin products), or immunosuppressants (e.g., methotrexate) must not have been taken in the prior month.\n3. Contraindications to ketoprofen, such as hypersensitivity to ketoprofen or history of upper or lower gastrointestinal bleeding.\n4. Have other major neurological or medical diseases that may cause cognitive dysfunction, such as structural brain diseases, metabolic diseases, paraneoplastic syndromes, infectious diseases, or other significant neurological abnormalities.\n5. Have an unstable medical condition that, in the opinion of the investigators, makes participation unsafe (e.g., an active infection or untreated malignancy).\n6. Are unable to travel to the NIH.\n7. Have recent exposure to radiation related to research (e.g., PET from other research) that, when combined with this study, would be above the allowable limits.\n8. Have an inability to lie flat and\u002For lie still on the camera bed for at least two hours, including claustrophobia, overweight greater than the maximum for the scanner, and uncontrollable behavioral symptoms, which will be screened by an interview with the patient and\u002For caregiver during the screening visit.\n9. Participants must not have substance use disorder or alcohol use disorder. However, alcohol or cannabis use by themselves are not exclusion criteria, unless that use impairs function of daily life.\n10. Participants should not be under treatment with Aduhelm, nor should they have been treated in the past.\n11. Are unable to have an MRI scan (e.g., because of pacemakers or other implanted electrical devices, brain stimulators, dental implants, aneurysm clips (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and cochlear implants), permanent eyeliner, implanted delivery pumps, shrapnel fragments, or metal fragments in the eye).\n12. Pregnancy\n13. HIV infection\n14. Be NIMH staff or an NIH employee who is a subordinate\u002Frelative\u002Fco-worker of the investigators.",true,"18 Years","99 Years",{"count":59,"type":21},184,"INTERVENTIONAL",[62],"PHASE1","Background:\n\nAbout 5 million adults in the U.S. have Alzheimer s disease or another adult-onset neurodegenerative disorder. Many studies have found that inflammation in the brain contributes to these diseases. Researchers want to find a better way to measure this inflammation.\n\nObjective:\n\nTo learn whether COX-1 and\u002For COX-2 is elevated in the brains of individuals with neurodegenerative brain disease compared to healthy volunteers.\n\nEligibility:\n\nAdults age 18 years and older in good general health who have an adult-onset neurodegenerative dementia, such as AD, FTD, corticobasal syndrome, Huntington s disease, or MCI, ALS and healthy adult volunteers enrolled in protocols 01-M-0254 or 17-M-0181.\n\nDesign:\n\nParticipants will be screened with medical history, physical exam with vital signs, and lab tests. They will have a neuropsychological testing. Their heart function will be measured.\n\nParticipants will have a magnetic resonance imaging (MRI) scan. The MRI scanner is a metal tube surrounded by a strong magnetic field. Participants will lie on a table that slides in and out of the tube. The machine makes noise. Participants will get earplugs.\n\nParticipants will have 2 PET scans. They will be injected with the study drugs through an intravenous catheter placed in an arm vein. The PET scanner is shaped like a doughnut. Participants will lie on a bed that slides in and out of the scanner. A plastic mask will be molded to their head to keep them from moving. A thin plastic tube will be put into an artery at the wrist or elbow crease area. This will be used to draw blood during the scan.\n\nParticipants will have 2-5 study visits. Participation lasts 1 week to 4 months, depending on scheduling.",[25,65,66,67,68],"Dementia","Alzheimer's Disease","ALS","Mild Cognitive Impairment",[70,71,72,65,73,67,74],"PET Imaging","PD","Inflammation","Cyclooxygenase-2","MCI","2026-07-01",{"date":77,"type":40},"2026-07-02",{"date":79,"type":40},"2021-08-17",{"date":81,"type":21},"2030-10-03",{"name":83,"class":84},"National Institute of Mental Health (NIMH)","NIH",1,{"id":87,"slug":4,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":16,"minAge":92,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":96,"conditions":97,"keywords":99,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":85},"100637658","NCT07629115","A Long-Term Follow-up Study of the Severe Parkinson's Disease Patients Administered the IPS101A Gene Therapy Product.","A Long-Term Follow-up Study to Evaluate the Safety and Efficacy of the Severe Parkinson's Disease Patients Administered the IPS101A Gene Therapy Product in the IPS101A-10 Phase I Clinical Trial","Inclusion Criteria\n\n* Subjects who were enrolled in the IPS101A-10 clinical trial and received IPS101A.\n* Subjects and\u002For their legally acceptable representatives who voluntarily provided written informed consent to participate in this long-term follow-up study after being fully informed of the study, and who agreed to comply with all study-related requirements.\n\nExclusion Criteria\n\n* Subjects who decline to provide consent for participation in the long-term follow-up study, or for whom follow-up assessments are not feasible due to death or other reasons.\n* Subjects who, in the judgment of the investigator, are considered unsuitable for participation in the study due to unwillingness or inability to comply with scheduled study visits or other study-related requirements.","50 Years","80 Years",{"count":95,"type":21},6,"The purpose of this study is to evaluate the long-term safety of IPS101A and to assess the durability of efficacy in subjects who received IPS101A.",[98,25],"Parkinson Disease",[100,101,102],"Adeno-associated Virus","Gene therapy","AAV","2026-06-29",{"date":75,"type":40},{"date":106,"type":40},"2026-05-29",{"date":108,"type":21},"2031-10-30",{"name":110,"class":47},"Innopeutics Corporation",{"id":112,"slug":4,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":16,"minAge":117,"maxAge":118,"enrollmentInfo":119,"targetDuration":4,"studyType":60,"phases":120,"briefSummary":121,"conditions":122,"keywords":123,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":125,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":85},"100508545","NCT05901818","Safety and Efficacy of Autologous iNSC-DAP in the Treatment of Parkinson's Disease","Safety and Efficacy of Autologous Induced Neural Stem Cell-derived Dopaminergic Precursor Cells in the Treatment of Parkinson's Disease","Inclusion Criteria:\n\nAges between 30 and 85 years, males or females; Diagnosed to be Parkinson's disease patients according to MDS Parkinson's disease diagnostic criteria; Disease history over 3 years; Hoehn and Yahr Stage less than or equal to 4 during the medication \"on\" time; Responsive to levodopa treatment (Maximum rate of improvement in MDS-UPDRS, part 3, is over 30%).\n\nExclusion Criteria:\n\nAtypical Parkinsonian syndrome or secondary Parkinsonian syndrome; Accompanied with other central nervous system diseases; With other severe systemic diseases or dysfunction; With severe psychiatric disorders; Subjects are using hormone or cytotoxic drugs and cannot stop taking the drug during the trial; With cognitive disorders (MMSE\\\u003C24); With severe dyskinesia (MDS-UPDRS part 4, score in 4.1\u002F4.2 ≥ 2); Subjects have undergone previous brain surgery; Subjects are long-term user of anticoagulant; Subjects have intracranial lesions which may affect the surgery or follow-up studies as assessed by imaging; Subjects are unable to undergo MRI or AV133 PET examination; Pregnancy or in preparation for pregnancy; Not suitable to participate in this clinical trial as assessed by the study investigators\u002Fphysicians.","30 Years","85 Years",{"count":95,"type":21},[62],"This is a phase I, interventional, single arm, open-label, clinical study to evaluate the safety and efficacy of the striatal transplantation of autologous induced neural stem cell-derived DA precursor cells in Parkinson's Disease patients.",[25],[124],"Autologous; iNSC; DA precursor cells; Parkinson's Disease; Cell therapy; Stereotaxic injection",{"date":75,"type":40},{"date":127,"type":40},"2021-04-01",{"date":129,"type":21},"2028-12-31",{"name":131,"class":132},"Xuanwu Hospital, Beijing","OTHER",{"id":134,"slug":4,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":60,"phases":140,"briefSummary":142,"conditions":143,"keywords":144,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":85},"100218336","NCT02119611","Deep Brain Stimulation Therapy in Movement Disorders","* INCLUSION CRITERIA:\n\nTo be eligible for entry into the study, candidates must meet all the following criteria:\n\n* Be 18 years of age or older.\n* Able to comply with study procedures and provide informed consent.\n* Have a clinical diagnosis of idiopathic PD, primary dystonia, or ET:\n\n  1. The diagnosis of idiopathic PD will be based on the UK Brain Bank Criteria, and confirmed by the Movement Disorders Neurologists in the NIH Parkinson Clinic.\n  2. The diagnosis of primary (generalized or segmental), hemidystonia, or cervical dystonia will be confirmed on clinical examination in the NIH Movement Disorders Clinic.\n  3. The diagnosis of ET will be confirmed on clinical examination in the NIH Movement Disorders Clinic (the diagnosis of ET will be based on bilateral, largely symmetric postural or kinetic tremor involving hands and forearms that is visible and persistent. Additional or isolated tremor in head may be present but there should be the absence of abnormal posturing).\n* a. History of appropriate response to dopaminergic medication, with at least a 30% improvement in motor UPDRS with L-DOPA by history or in-clinic testing, for the PD patients. OR\n\n  b.Patients with tremor-dominant PD that do not respond to dopaminergic therapy and that exhibit a tremor score of at least 2 for tremor severity on at least one side of the body on the motor UPDRS examination.\n* Unsatisfactory clinical response to maximal medical management (with trials of both higher and lower doses of drugs), including:\n\nFor PD patients:\n\n1. good benefit from dopaminergic medication but associated with insufficient duration of action or unacceptable side-effects OR\n2. intractable disabling motor fluctuations (severe off periods, dyskinesias, or freezing spells) OR\n\n   For ET and dystonia:\n3. intractable symptoms of ET or dystonia impacting at least 2 activities of daily living.\n\n   * Interested in being evaluated to undergo DBS, if indicated, to treat medically refractory movement disorder or\n   * Patients already implanted with DBS for continued management\n\n(Note: Inclusion criteria 4 and 5 can be met by historical report in patients who had DBS implanted outside the NIH)\n\nEXCLUSION CRITERIA:\n\nFor those who have not had DBS:\n\nCandidates will be excluded if they meet any of the following criteria:\n\n* Clinically significant medical disease that would increase the risk of developing pre- or postoperative complications, including but not limited to uncontrolled systemic hypertension with values above 170\u002F100; unstable heart disease; unstable respiratory disease; uncorrected coagulation abnormalities or need for therapeutic anticoagulation which cannot be interrupted;\n* Evidence of secondary or atypical parkinsonism\u002Fdystonia\u002Ftremor as suggested by:\n\n  1. History of stroke, exposure to toxins, neuroleptics, or encephalitis\n  2. Neurologic signs of upper motor neuron or cerebellar involvement, supranuclear gaze palsy, or multiple systems atrophy.\n  3. MR-imaging with evidence indicative of secondary disease such as tumor, or stroke, which could cause the movement disorder.\n* Dementia as evidenced by formal neuropsychological evaluation, Mattis Dementia Rating Scale (DRS-2) score, and clinical evaluations.\n* Unable to complete cognitive assessments and testing necessary to adequately evaluate risks and benefits of surgery.\n* Clinically signficiant or unstable psychiatric disorder such as severe depression or anxiety, which, in the opinion of the investigators would increase the risk of developing postoperative complications.\n* Unable to undergo MR-imaging because of implanted pacemakers, medication pumps, aneurysm clips, metallic prostheses (including metal pins and rods, heart valves or cochlear implants), shrapnel fragments, permanent eye liner or small metal fragments in the eye that welders and other metal workers may have, or if candidates are uncomfortable in small closed spaces (have claustrophobia), or cannot lie comfortably on their back for up to one hour.\n* Pregnant women.\n* Otherwise not eligible for DBS surgery, for example known inability to undergo anesthesia\n\nFor those who have had DBS:\n\n-Contra-indications for ongoing stimulation, such as intractable side effects of DBS despite stimulation parameter adjustment","100 Years",{"count":20,"type":21},[141],"NA","Background:\n\n\\- In deep brain stimulation (DBS), a device called a neurostimulator is placed in the chest. It is attached to wires in parts of the brain that affect movement. DBS might help people with movement disorders like Parkinson s disease (PD), dystonia, and essential tremor (ET).\n\nObjective:\n\n\\- To provide DBS treatment to people with some movement disorders.\n\nEligibility:\n\n\\- Adults 18 years and older with PD, ET, or certain forms of dystonia.\n\nDesign:\n\n* Participants will be screened with medical history and physical exam. They will have blood and urine tests and:\n* MRI brain scan. The participant will lie on a table that slides in and out of a metal cylinder with a magnetic field. They will be in the scanner about 60 minutes. They will get earplugs for the loud noises. During part of the MRI, a needle will guide a thin plastic tube into an arm vein and a dye will be injected.\n* Electrocardiogram. Metal disks or sticky pads will be placed on the chest, arms, and legs. They record heart activity.\n* Chest X-ray.\n* Tests of memory, attention, concentration, thinking, and movement.\n* Eligible participants will have DBS surgery. The surgery and hospital care afterward are NOT part of this protocol.\n* Study doctors will see participants 3 4 weeks after surgery to turn on the neurostimulator.\n* Participants will return every month for 3 months, then every 3 months during the first year, and every 6 months during the second year. Each time, participants will be examined and answer questions. DBS placement will be evaluated with MRI. The neurostimulator will be programmed. At two visits, participants will have tests of movements, thinking, and memory....",[25],[145,146,25,147,148],"Deep Brain Stimulation","Movement Disorders","Essential Tremor","Tourette Syndrome","2026-06-27",{"date":151,"type":40},"2026-06-30",{"date":153,"type":40},"2014-04-02",{"date":155,"type":21},"2030-12-01",{"name":157,"class":84},"National Institute of Neurological Disorders and Stroke (NINDS)",{"id":159,"slug":4,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":16,"minAge":117,"maxAge":93,"enrollmentInfo":164,"targetDuration":4,"studyType":60,"phases":166,"briefSummary":167,"conditions":168,"keywords":171,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":85},"100636786","NCT07570212","Individualized Transcranial Magnetic Stimulation in Parkinsonian Disorders","Exploration of the Efficacy of Individualized Transcranial Magnetic Stimulation in the Treatment of Parkinsonian Disorders","Inclusion Criteria:\n\n1. Diagnostic Criteria Clinically established or clinically probable Parkinson's Disease (PD) according to the 2015 International Parkinson and Movement Disorder Society (MDS) diagnostic criteria; Clinically established or clinically probable Multiple System Atrophy (MSA) according to the 2022 MDS diagnostic criteria; Clinically probable or clinically possible Progressive Supranuclear Palsy (PSP) according to the 2017 MDS diagnostic criteria.\n2. Demographics Aged 30 to 80 years, inclusive; no gender restrictions.\n3. Disease Severity and Staging PD: Modified Hoehn and Yahr (H-Y) stage 2-4; MSA: Unified Multiple System Atrophy Rating Scale (UMSARS) Part IV stage 1-4; PSP: Modified Rankin Scale (mRS) grade 2-4.\n4. Informed Consent and Compliance Ability to understand and comply with the study requirements and provide written informed consent.\n\nExclusion Criteria:\n\n1. Contraindications to TMS Presence of intracranial metallic implants or other foreign bodies, including but not limited to cochlear implants, cardiac pacemakers, or internal metallic\u002Fmagnetic fragments.\n2. Contraindications to EEG and MRI EEG: Known allergy to conductive paste or other EEG-related contraindications. MRI: History of claustrophobia, presence of MRI-incompatible implants, or extensive tattoos.\n3. Concurrent Physical Therapies Currently receiving Transcranial Magnetic Stimulation (TMS) or other therapeutic physical modalities, such as Transcranial Direct Current Stimulation (tDCS).\n4. Unstable Medical Conditions Presence of unstable systemic diseases requiring urgent pharmacological or surgical intervention.\n5. Neurological and Psychiatric History Personal or family history of epilepsy; History of moderate-to-severe psychiatric or psychological disorders; Chronic insomnia or regular use of sedative-hypnotics; Current use of medications that significantly alter central nervous system excitability.",{"count":165,"type":21},50,[141],"This clinical trial aims to evaluate whether individualized targeted repetitive transcranial magnetic stimulation (rTMS) can improve motor and non-motor symptoms in patients with parkinsonian disorders. The main question it aims to answer is:\n\n* Does individualized targeted rTMS alleviate symptoms of parkinsonian disorders?\n* Which clinical manifestations of parkinsonian syndromes are responsive to individualized targeted rTMS, and to what degree?\n\nProcedures:\n\n* Preparation (Screening) Participants will undergo clinical assessments, MRI, and EEG before the treatment.\n* Treatment (2 Weeks) Participants will receive a 10-day TMS treatment (once daily, Monday-Friday). Each treatment day takes approximately 3-4 hours. Participants need to keep stable medications and rehabilitation routines during this time.\n* Follow-up (10 Weeks) Participants will undergo follow-up assessments at the end of treatment and 10 weeks after treatment. Assessments include clinical scales, MRI, and EEG.",[25,169,170],"Multiple System Atrophy","Progressive Supranuclear Palsy",[172,173,174],"parkinsonian disorders","transcranial magnetic stimulation","somato-cognitive action network","2026-06-24",{"date":103,"type":40},{"date":178,"type":40},"2025-12-22",{"date":180,"type":21},"2027-12-22",{"name":182,"class":132},"Peking University First Hospital",{"id":184,"slug":4,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":55,"sex":16,"minAge":56,"maxAge":93,"enrollmentInfo":189,"targetDuration":4,"studyType":60,"phases":191,"briefSummary":193,"conditions":194,"keywords":197,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":210},"100619717","NCT07348250","Open-label Study to Evaluate Brain α-Synuclein Deposition Using PET and [18F]MK-0947 in Parkinson's Disease","An Open-label Study to Evaluate Brain α-Synuclein Deposition Using Positron Emission Tomography (PET) and [18F]MK-0947 in Patients With Parkinson's Disease","Inclusion Criteria:\n\n* Signed informed consent prior to any study procedures\n* Women of childbearing potential: abstinent or use 2 contraception methods (one barrier) during study and 90 days post last injection\n* Men: use 2 contraception methods and refrain from sperm donation during study and 90 days post last injection\n* PD \\& HE participants: Age 40-80 years; HP participants: Age 18-50 years\n* Adequate circulation and normal clotting for arterial cannulation (if applicable)\n* HE participants: no neurological disorder, no first-degree relative with idiopathic PD\n* HP participants: healthy with no clinically relevant findings\n\nExclusion Criteria:\n\n* Unwilling or unable to provide informed consent\n* Clinically significant hepatic, renal, cardiovascular, pulmonary, or systemic illness\n* Pregnant or breastfeeding\n* Contraindication to PET or MRI procedures (e.g., implants, claustrophobia)\n* History of severe allergic reactions to PET tracers or related compounds\n* Current or prior participation in investigational drug study within 30 days\n* Any condition that may interfere with study conduct or participant safety",{"count":190,"type":21},22,[192],"EARLY_PHASE1","This clinical study is being conducted to learn more about a new imaging drug called \\[18F\\]MK-0947, which is designed to help doctors see changes in the brain related to Parkinson's disease (PD). PD is a condition that affects movement, balance, and thinking. The drug works with a type of scan called PET (Positron Emission Tomography) to show areas of the brain where a protein called α-synuclein builds up. This buildup is linked to PD and other brain disorders.\n\nThe main goal of this study is to find out if \\[18F\\]MK-0947 is safe for people and if it works well to show α-synuclein in the brain. The study will also look at how the drug moves through the body and how much radiation it gives off. Researchers hope this information will help develop better tools for diagnosing PD and tracking how it changes over time.\n\nWho can join? Adults who have PD or who are healthy may be able to take part. Participants will have screening tests to make sure they qualify.\n\nWhat does participation involve? People in the study will have PET scans, blood tests, and other safety checks. Some participants will also have an MRI scan. The study is divided into two parts: Part 1 looks at how the drug works in the brain of PD patients and healthy elderly participants, and Part 2 measures radiation levels in healthy participants.\n\nWhy is this important? There is currently no cure for PD, and better imaging tools could help researchers develop new treatments. By joining this study, participants will help advance research that may improve care for people with PD and similar conditions in the future.",[195,25,196],"Parkinson's Disease (PD)","Parkinson's Disease (Disorder)",[198,199,200,201],"alpha-synuclein","α-synuclein","Neurodegeneration","MK-0947",{"date":203,"type":40},"2026-06-26",{"date":205,"type":40},"2025-12-08",{"date":207,"type":21},"2026-12",{"name":209,"class":132},"Invicro",2,{"id":212,"slug":4,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":214,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":4,"enrollmentInfo":216,"targetDuration":4,"studyType":60,"phases":218,"briefSummary":219,"conditions":220,"keywords":221,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":222,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":229},"100609622","NCT07216976","Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease (ADAPT-PD) China Study","Inclusion Criteria:\n\n1. Subjects must meet all general inclusion\u002Fexclusion criteria (as assessed at the Enrollment Visit)\n2. Subjects must meet the LFP screening inclusion criterion (as assessed at the LFP Screening Visit)\n\nGeneral (Assessed at Enrollment Visit):\n\n1. Subject has idiopathic Parkinson's disease\n2. Subject is implanted (\\>3 months prior to enrollment for new INS implants or \\>1 month from INS replacement) with a Percept PC (Model B35200) or Percept RC (Model B35300) and Medtronic DBS leads (Model 3387, 3389, B33005 or B33015) and extensions (Model 37086 or B34000) bilaterally in the same target (physician confirmed), STN or GPi\n3. In the opinion of the investigator, the subject responds to DBS Therapy.\n4. Based on the opinion of the investigator, the subject's cDBS parameters and PD medications are stable (no changes within the last 4 weeks) and expected to remain stable from enrollment through the end of the aDBS Evaluation Phase\n5. Subject is configured to monopolar or dual monopolar stimulation using contacts 1 and\u002For 2 (9 and\u002For 10) on at least one side\n6. Subject is willing and able to attend all study-required visits and complete the study procedures (e.g. 1-month recall questionnaires, MDS-UPDRS III, Off stim\u002FOff med visit)\n7. Subject (or legally authorized representative) has the ability to understand and provide written informed consent for participation in the study prior to the study-related procedures being conducted\n8. Subject is a male or non-pregnant female. If female of child-bearing potential, and if sexually active, must be using, or agree to use, a medically-acceptable method of birth control as confirmed by the investigator\n\nLFP Screening Inclusion Criteria (Conducted during LFP Screening Visit):\n\n1\\. Subject has Alpha - Beta band (8-30 Hz) amplitude ≥ 1.2 μVp detected on either left and\u002For right DBS leads on sensing channels 0-2, 0-3, 1-3, 8-10, 8-11, or 9-11.\n\nExclusion Criteria:\n\nGeneral (Assessed at the Enrollment Visit):\n\n1. Subject and\u002For caregiver is unable to utilize the patient programmer\n2. Subject has more than one lead in each hemisphere of the brain\n3. Subject has cortical leads or additional unapproved hardware implanted in the brain\n4. Subject has more than one INS\n5. At enrollment, the subject's INS has a predicted battery life of \\\u003C1 year\n6. Subject has Beck Depression Inventory II (BDI-II)\\>25\n7. Subject requires diathermy, transcranial magnetic stimulation (TMS), or electroconvulsive therapy (ECT)\n8. Subject has a metallic implant in the head, (e.g., aneurysm clip, cochlear implant)\n9. Subject has, or plans to obtain, an implanted electrical stimulation medical device anywhere in the body (e.g., cardiac pacemaker, defibrillator, spinal cord stimulator)\n10. Subject has, or plans to obtain, an implanted medication pump for the treatment of Parkinson's disease (e.g., DUOPATM infusion pump) and\u002For portable infusion pump\n11. Based on the opinion of the investigator, the subject has an abnormal neurological examination that would preclude them from study participation\n12. Subject is breast feeding\n13. Subject is under the age of 18 years\n14. Subject is currently enrolled in or plans to enroll in any concurrent drug and\u002For device study that may confound the results of this study as determined by the Medtronic study team\n15. Subjects with signal artifact on all 6 aDBS sense pathways (3 each on both DBS leads) which preclude the clinician from setting thresholds",{"count":217,"type":21},62,[141],"The purpose of the study is to evaluate the effectiveness of the Medtronic Adaptive DBS therapy (aDBS) for Parkinson's Disease in China with the Percept family of Implantable Neurostimulators (Percept PC and Percept RC).",[25],[145],{"date":203,"type":40},{"date":224,"type":40},"2025-11-19",{"date":226,"type":21},"2028-01",{"name":228,"class":47},"MedtronicNeuro",5,{"id":231,"slug":4,"hasResults":11,"nctId":232,"briefTitle":233,"officialTitle":233,"acronym":4,"eligibilityCriteria":234,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":235,"targetDuration":4,"studyType":60,"phases":237,"briefSummary":238,"conditions":239,"keywords":242,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":245,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":85},"100567700","NCT06671600","Effects of Osteopathic Manipulative Treatment Protocol on Sleep Quality in Parkinson's Disease Subjects","Inclusion Criteria:\n\n* Must have a diagnosis of Parkinson's disease as per a neurologist\n* Severity of 0-3 on the Hoehn and Yahr (H-Y) Scale\n* Able to receive OMM\n* Able to be in a supine and prone position.\n* Able to wear a Fitbit watch and an oxygen saturation ring for the duration of the study (including when sleeping).\n* Have sleep disturbance complaints.\n\nExclusion Criteria:\n\n* Patients on medications that affect sleep\n* Have a pre-existing sleep disorder diagnosis\n* Those who have a concurrent neurological diagnosis that would confound sleep patterns (ie. narcolepsy)\n* Contraindications to the OMM techniques used in this protocol\n* Severity of 4 and 5 on the Hoehn and Yahr Scale",{"count":236,"type":21},32,[141],"Parkinsonism, mainly caused by Parkinsons disease (PD), includes symptoms like tremors, stiffness, slow movements, and balance problems. These symptoms can make it hard for people to sleep well, which leads to a lower quality of life and can increase the risk of other health issues and cognitive decline.\n\nOsteopathic manipulative treatment (OMT) is a hands-on approach that may help improve sleep without the side effects of traditional treatments. While OMT has shown promise in enhancing sleep, no studies have specifically looked at its effects on sleep in Parkinson's disease patients.\n\nThis study aims to see if OMT can help improve sleep quality, cognitive function, and daily activities for people with PD. The investigators will focus on treating specific areas of the body, using techniques that have helped improve sleep in the past.\n\nParticipants will be divided into two groups: one will receive OMT, while the other will get a light touch treatment as a control. Sleep surveys and data from Fitbit devices will be used to compare the effects of the two treatments. Additionally, cognitive function will be assessed using a specific task called the Stroop task.\n\nThis research could show that OMT can be a valuable addition to treatments for improving sleep quality in people with Parkinsons disease.",[240,241],"Parkinsons Disease","Sleep",[243,241,240,244],"OMM","Osteopathy",{"date":103,"type":40},{"date":247,"type":40},"2025-08-01",{"date":249,"type":21},"2027-12-31",{"name":251,"class":132},"New York Institute of Technology",{"id":253,"slug":4,"hasResults":11,"nctId":254,"briefTitle":255,"officialTitle":255,"acronym":4,"eligibilityCriteria":256,"healthyVolunteers":55,"sex":16,"minAge":257,"maxAge":138,"enrollmentInfo":258,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":260,"conditions":261,"keywords":264,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":266,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":85},"100471009","NCT05413291","Natural History Protocol for Movement Disorders","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Male or female, aged 2 and above\n* Either one of these:\n\n  * Have or suspected to have a diagnosis of a movement disorder.\n  * Family member of someone who has or is suspected of having a diagnosis of a movement disorder.\n* Ability of subject or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets the following criteria will be excluded from participation in this study:\n\n-Being \\\u003C 2 years old.","2 Years",{"count":259,"type":21},4000,"Background:\n\nA movement disorder is a condition that causes a person s body to move in ways that are not normal. There are different types. Some disorders cause movements people can t control, such as tics or shaking. Some cause reduced or slow movements. Movement disorders can cause disability in people. Sometimes members of the same family will have the same disorder. Researchers want to learn more about how people develop these disorders. This research could lead to better treatments.\n\nObjective:\n\nThis natural history study will collect data on people with different types of movement disorders. It will also collect data on their family members. The data will support further research.\n\nEligibility:\n\nChildren and adults aged 2 years and older who have a movement disorder. Family members of people with movement disorders are also needed.\n\nDesign:\n\nParticipants will undergo screening. They will have a physical exam. Researchers will look at their existing medical images. Any photographs or videos of their movements will also be reviewed.\n\nMost participants will come to the NIH clinic for only 1 visit. They will answer questions about their condition. They will have normal tests used to diagnose their condition. They may have blood tests and different types of imaging scans. They may have tests to see how well their nerves function. The tests used will depend on the type of disorder they have.\n\nFamily members will have some of the same tests as people with disorders.\n\nParticipants will not receive any new treatments.\n\nSome participants may be asked to return for a follow-up visit.\n\nUp to 4000 people may participate.",[262,263,25],"Movement Disorder","Tremor",[262,263,25,265],"Natural History",{"date":267,"type":40},"2026-06-25",{"date":269,"type":40},"2022-10-17",{"date":271,"type":21},"2030-12-31",{"name":157,"class":84},{"id":274,"slug":4,"hasResults":11,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":278,"eligibilityCriteria":279,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":4,"enrollmentInfo":280,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":282,"conditions":283,"keywords":284,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":295},"100622347","NCT07382440","A Study to Assess Change in Disease Symptoms in Adult Participants With Advanced Parkinson Disease Using Subcutaneous Foslevodopa\u002FFoscarbidopa in Belgium","Observational Prospective Study to Evaluate Effectiveness of Subcutaneous Treatment With Foslevodopa\u002FFoscarbidopa in Real Life Setting for Advanced Parkinson's Disease Patients in Belgium.","ProParkB","Inclusion Criteria:\n\n* Participant diagnosed with Advanced Parkinson's Disease (PD), aged 18 years or older able to provide voluntary informed consent.\n* Participant evaluated for commercially available continuous subcutaneous Foslevodopa\u002FFoscarbidopa (LDp\u002FCDp) in the hospital at the clinician's discretion as part of his\u002Fher routine clinical care and the intention to administer subcutaneous LDp\u002FCDp made prior to and independent of recruitment into the study.\n\nExclusion Criteria:\n\n* Participant participating in an interventional research study (not including noninterventional studies) during the administration of LDp\u002FCDp.\n* Participant evaluated for commercially available continuous subcutaneous LD\u002FCDp outside of the hospital.",{"count":281,"type":21},120,"Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. This study will assess how effective Foslevodopa\u002FFoscarbidopa is in treating adult participants with advanced Parkinson Disease under routine clinical practice in Belgium.\n\nFoslevodopa\u002FFoscarbidopa is an approved drug for the treatment of Parkinson's Disease. Approximately 120 adult participants who are prescribed Foslevodopa\u002FFoscarbidopa by their doctors will be enrolled at 15 sites across Belgium.\n\nParticipants will receive Foslevodopa\u002FFoscarbidopa subcutaneous infusion as prescribed by their physician. Participants will be followed for up to 18 months.\n\nThere is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.",[25],[285,286],"Parkinson's Disease: Advanced Parkinson's Disease","Foslevodopa\u002FFoscarbidopa","2026-06-23",{"date":267,"type":40},{"date":290,"type":40},"2026-03-09",{"date":292,"type":21},"2028-09",{"name":294,"class":47},"AbbVie",12,{"id":297,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":298,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":299,"keywords":300,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":307,"locationsCount":48},"100618333",{"count":20,"type":21},[25],[27,28,29,30,31,32,33,34,35],"2026-06-12",{"date":303,"type":40},"2026-06-15",{"date":305,"type":40},"2026-06-10",{"date":44,"type":21},{"name":46,"class":47},{"id":309,"slug":4,"hasResults":11,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":4,"eligibilityCriteria":313,"healthyVolunteers":11,"sex":16,"minAge":314,"maxAge":93,"enrollmentInfo":315,"targetDuration":4,"studyType":60,"phases":317,"briefSummary":318,"conditions":319,"keywords":4,"overallStatus":324,"whyStopped":4,"lastUpdateSubmitDate":325,"lastUpdatePostDateStruct":326,"startDateStruct":328,"completionDateStruct":329,"leadSponsor":331,"locationsCount":4},"100641633","NCT07653256","HF-rTMS Primed Balance Training on Corticomotor Excitability, Balance, and Gait in Parkinson's","Effects of High-frequency Repetitive Transcranial Magnetic Stimulation-primed Balance Training on Corticomotor Excitability, Balance, and Gait Performance in Parkinson's Disease","Inclusion Criteria:\n\n* Diagnosed with idiopathic PD\n* Aged between 40-80 years\n* Stable on antiparkinsonian medication ( \\> 3 months)\n* H\\&Y I-III\n* Able to walk continuously for at least 10 minutes\n* The ability to follow commands and instructions\n\nExclusion Criteria:\n\n* Neurological diseases other than PD\n* Severe musculoskeletal, cardiopulmonary disorders\n* MMSE \\\u003C 24\n* Contraindications for TMS\n* Have undergone or are scheduled to undergo neurological surgery during the study participation period","40 Years",{"count":316,"type":21},20,[141],"This study aims to investigate the effects of repeated transcranial magnetic stimulation combined with modified otago exercise program balance training intervention on motor cortex excitability, balance, and gait performance in patients with Parkinson's disease.",[25,320,321,322,323],"Corticomotor Excitability","Balance Control","Gait Performance","Motor Symptoms","NOT_YET_RECRUITING","2026-06-11",{"date":327,"type":40},"2026-06-17",{"date":75,"type":21},{"date":330,"type":21},"2028-04-01",{"name":332,"class":132},"Chung Shan Medical University",{"id":334,"slug":4,"hasResults":11,"nctId":335,"briefTitle":336,"officialTitle":337,"acronym":4,"eligibilityCriteria":338,"healthyVolunteers":11,"sex":16,"minAge":314,"maxAge":118,"enrollmentInfo":339,"targetDuration":4,"studyType":60,"phases":341,"briefSummary":342,"conditions":343,"keywords":344,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":325,"lastUpdatePostDateStruct":353,"startDateStruct":354,"completionDateStruct":356,"leadSponsor":358,"locationsCount":85},"100634156","NCT07536022","At-home taVNS for Neurorehabilitation in Parkinson's Disease","Developing At-home taVNS for Neurorehabilitation in Parkinson's Disease","Inclusion Criteria:\n\n* Issues with walking, balance, and gait as determined by a movement disorders neurologist (a score of equal to or greater than 1 on MDS-UPDRS items 2.12 (walking and balance), and 3.10 (gait))\n* Diagnosis of idiopathic Parkinson's Disease based on UK Brain Bank diagnostic criteria\n* Hoehn and Yahr Stage 2-4 as determined by a movement disorders neurologist\n* Stable on dopaminergic medications over the past 30 days prior to enrollment in the study\n\nExclusion Criteria:\n\n* A history of taVNS in the last 6 months\n* A history of brain surgery, traumatic brain injury or stroke\n* Diagnosis of a nervous system disorder besides PD, alcohol or substance use disorder, or unstable cardiovascular conditions\n* History of myocardial infarction or arrhythmia, bradycardia\n* A history of other significant gait impairment unrelated to PD (e.g. orthopedic deformities)\n* Inability to complete gait\u002F motor assessments (without assistance or assistance devices)\n* Ear trauma, facial pain, anatomical abnormalities or other barriers preventing earpiece fit\n* Failure to meet all criteria on a standardized MRI\u002FtaVNS safety screening: This includes, but is not limited to, the presence of claustrophobia, implanted electronic devices that are not 3T MRI compatible (e.g., pacemakers), metallic objects or fragments (e.g., bullets), and non-removable hair clips or piercings.\n* Individuals with a diagnosis of cognitive impairment (MoCA \\\u003C 24) that would make them unable to understand and follow study instructions or to consent for themselves.\n* Pregnancy\n* Visual hallucinations or other psychotic symptoms, other than mild visual hallucinations secondary to PD medications, not requiring treatment, or well controlled on stable doses of quetiapine or pimavenserin.\n* Individuals with a history of seizure(s)\n* Inability to perform at-home taVNS procedures safely and properly (either alone or with the aid of a caregiver)\n* Uncorrected visual or hearing impairments that would impact performance on cognitive tests or ability to follow study procedures\n* Use of B-Blockers, dopamine blocking agent (other than quetiapine or pimavenserin in stable doses), antiarrhythmic medication, acetylcholine esterase inhibitor (study doctor will consider if on stable doses), midodrine, fludrocortisone, droxidopa, or anticholinergic drugs",{"count":340,"type":21},16,[141],"The goal of this clinical trial is to learn if taVNS works to treat symptoms of Parkinson's Disease in adults. It will also learn about the feasibility and preliminary efficacy of taVNS administered at home by the participant.\n\nThe main questions it aims to answer are:\n\n1. Is at-home taVNS feasible and effective for treating symptoms of Parkinson's Disease? How often are participants completing the stimulation protocol? What are the side effects of stimulation experienced by participants? How do participants rate the experience of taVNS sessions at home? How do participants' scores on assessments and questionnaires change with taVNS treatments?\n2. How does taVNS impact connections between neural networks in the brain of patients with Parkinson's Disease at rest?\n\nParticipants will:\n\n* Have a baseline MRI scan to take images of their brain.\n* Complete a series of assessments and questionnaires to evaluate their Parkinson's Disease motor symptoms, cognitive and neuropsychiatric symptoms, and other non-motor symptoms.\n* Have an initial taVNS session where their threshold to perceive the stimulation will be measured. This value will be used to stimulate each participant at a specific dose relative to their individual perception of stimulation.\n* Be trained on how to use the taVNS device and system and have one 1-hour taVNS session where their vitals will be monitored.\n* Self-administer 1-hour daily taVNS sessions for 8 weeks at-home, complete tolerability questionnaires, and weekly remote check-ins with study staff.\n* After 4-weeks of at-home taVNS, participants will come in-person to repeat the questionnaires and assessments from the first visit.\n* Following the 8 weeks of taVNS sessions, participants will repeat the MRI scan, assessments and questionnaires from visit 1.\n* Participants will complete questionnaires remotely 1 month following their last taVNS sessions.",[25],[25,345,346,347,348,349,350,351,352],"parkinsons","parkinson's","taVNS","transcutaneous vagus nerve stimulation","non-invasive brain stimulation","transcutaneous auricular vagus nerve stimulation","gait","motor symptoms",{"date":303,"type":40},{"date":355,"type":40},"2026-06-01",{"date":357,"type":21},"2027-06",{"name":359,"class":132},"Medical University of South Carolina",{"id":361,"slug":4,"hasResults":11,"nctId":362,"briefTitle":363,"officialTitle":363,"acronym":4,"eligibilityCriteria":364,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":4,"enrollmentInfo":365,"targetDuration":367,"studyType":22,"phases":4,"briefSummary":368,"conditions":369,"keywords":370,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":373,"startDateStruct":374,"completionDateStruct":376,"leadSponsor":378,"locationsCount":380},"100214628","NCT02071134","Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry","Key Inclusion Criteria:\n\n* Meets criteria established in locally applicable Vercise System Direction for Use\n* At least 18 years old\n\nKey Exclusion Criteria:\n\n* Meets any contraindication in the Vercise System locally applicable Directions for Use\n\nSubjects with significant cognitive or psychiatric impairment may be excluded in the evaluation of GXT.",{"count":366,"type":21},1500,"3 Years","The purpose of this registry is to compile characteristics of world-wide outcomes for the use of Boston Scientific's commercially available Vercise DBS System in the treatment of Parkinson's disease.\n\nThe utilization of Image Guided Programming (IGP), and other commercially available programming features, used as planning tools for the programming of patients with Boston Scientific's Vercise DBS System are also evaluated.\n\nAdditionally, the utilization of the DBS Illumina 3D feature that may be used for the programming of patients with Boston Scientific's Vercise DBS Systems is also evaluated.",[25],[371,28,372],"Deep brain stimulation","Vercise",{"date":301,"type":40},{"date":375,"type":40},"2014-03-04",{"date":377,"type":21},"2038-12",{"name":379,"class":47},"Boston Scientific Corporation",84,{"id":382,"slug":4,"hasResults":11,"nctId":383,"briefTitle":384,"officialTitle":384,"acronym":4,"eligibilityCriteria":385,"healthyVolunteers":11,"sex":16,"minAge":92,"maxAge":4,"enrollmentInfo":386,"targetDuration":4,"studyType":60,"phases":387,"briefSummary":388,"conditions":389,"keywords":390,"overallStatus":324,"whyStopped":4,"lastUpdateSubmitDate":394,"lastUpdatePostDateStruct":395,"startDateStruct":396,"completionDateStruct":398,"leadSponsor":400,"locationsCount":85},"100622501","NCT07384442","Effects of Targeted Temporal Interference Stimulation of Cerebellar Nuclei on Tremor and Gait Disturbance in Parkinson's Disease Patients","Inclusion Criteria:\n\n* 1.Aged 50 years or older;\n* 2.Confirmed diagnosis of idiopathic Parkinson's disease (IPD) according to the 2015 MDS diagnostic criteria, with tremor and gait disturbance;\n* 3.Disease duration ≥2 years after diagnosis, stable condition, and ability to cooperate with study assessment and intervention;\n* 4.Stable medication dosage for at least 4 weeks prior to the trial;\n* 5.Good response to Levodopa therapy;\n* 6.Capable of independent walking (without assistive devices) for at least 5 minutes and able to complete gait testing independently.\n* 7.Signed informed consent form, with the participant or their legal guardian able to understand and willing to participate in this study.\n\nExclusion Criteria:\n\n* 1.History or confirmed diagnosis of severe mental disorders, such as depression, anxiety disorders, schizophrenia spectrum disorders, and bipolar disorder;\n* 2.The subject has clinically defined neurological conditions (assessed through self-report), including but not limited to: any disease potentially associated with increased intracranial pressure, space-occupying lesions, stroke history, transient ischemic attack (TIA) within the past two years, cerebral aneurysm, dementia, multiple sclerosis;\n* 3.Severe cognitive impairment, Mini-Mental State Examination (MMSE) score \\\u003C22, or inability to independently complete questionnaires;\n* 4.Inability to read or understand Chinese;\n* 5.Use of other neuromodulatory therapies within the past 3 months;\n* 6.Presence of musculoskeletal or orthopedic conditions (e.g., severe arthritis, recent fractures) that significantly interfere with gait or balance;\n* 7.Presence of metal implants (e.g., Deep Brain Stimulation, cardiac pacemakers) or contraindications for MRI\u002FTIS;\n* 8.Current use of medications that affect dopamine levels (e.g., antipsychotics);\n* 9.Severe cardiovascular disease or other unstable medical conditions that preclude physical exertion or study participation;",{"count":165,"type":21},[141],"The goal of this clinical trial is to explore the effects of cerebellar nuclei TIS stimulation on improving tremor and gait disorders in PD patients. Through randomized double-blind grouping, the differences in efficacy between TIS intervention and sham stimulation intervention for tremor and gait disorders in PD patients will be compared.",[25,146],[25,391,146,263,392,393],"Cerebellar Nuclei","Gait","Temporal Interference Stimulation","2026-06-09",{"date":305,"type":40},{"date":397,"type":21},"2026-08-19",{"date":399,"type":21},"2026-12-31",{"name":401,"class":132},"YangPan",{"id":403,"slug":4,"hasResults":11,"nctId":404,"briefTitle":405,"officialTitle":406,"acronym":4,"eligibilityCriteria":407,"healthyVolunteers":11,"sex":16,"minAge":92,"maxAge":4,"enrollmentInfo":408,"targetDuration":4,"studyType":60,"phases":410,"briefSummary":412,"conditions":413,"keywords":416,"overallStatus":324,"whyStopped":4,"lastUpdateSubmitDate":394,"lastUpdatePostDateStruct":419,"startDateStruct":420,"completionDateStruct":421,"leadSponsor":423,"locationsCount":85},"100622500","NCT07384429","Effects of Lemborexant on Motor-sleep Comorbidity in Parkinson's Disease","Study for the Dual Orexin Receptor Antagonist Lemborexant in Improving Motor-Sleep Comorbidity in Parkinson's Disease","Inclusion Criteria:\n\n* 1\\. Aged 50 years or older;\n* 2\\. Diagnosed with idiopathic Parkinson's disease according to the Movement Disorder Society Clinical Diagnostic Criteria for Parkinson's Disease (2015), with a Hoehn \\& Yahr stage of 1 to 4;\n* 3\\. Disease duration of ≥ 2 years since diagnosis, clinically stable, and able to comply with the research assessments and interventions;\n* 4\\. Diagnosis of insomnia disorder meeting the criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), with an Insomnia Severity Index (ISI) score of ≥ 15;\n* 5\\. Stable medication regimen for at least 4 weeks prior to the study;\n* 6\\. Signed informed consent form, with the participant or their legal guardian able to understand and willing to participate in this study.\n\nExclusion Criteria:\n\n* 1\\. History of or diagnosis with a severe psychiatric disorder, such as depression, anxiety disorders, schizophrenia spectrum disorders, or bipolar disorder;\n* 2\\. Presence of a clinically defined neurological disorder (assessed via self-report), including but not limited to: any condition potentially associated with increased intracranial pressure, space-occupying brain lesions, history of stroke, transient ischemic attack within the past 2 years, cerebral aneurysm, dementia, or multiple sclerosis;\n* 3\\. Severe cognitive impairment (Mini-Mental State Examination (MMSE) score below 24) or inability to complete questionnaires independently;\n* 4\\. Chronic obstructive pulmonary disease (COPD) or any lifelong history of sleep-related breathing disorders, such as sleep apnea;\n* 5\\. Excessive daytime sleepiness, defined as self-reported daily daytime napping ≥ 1 hour per day on ≥ 3 days per week;\n* 6\\. Regular caffeine consumption;\n* 7\\. Use of any orexin receptor related medication within the past 3 months.\n* 8\\. Previous history of cataplexy or known reduced orexin levels;\n* 9\\. Inability to read or understand Chinese;\n* 10\\. Use of other sleep-promoting medications within the past 3 months.",{"count":409,"type":21},44,[411],"PHASE4","The aim of this study is to explore the effects of the dual orexin receptor antagonist Lemborexant on improving motor and sleep comorbidity in patients with Parkinson's disease. This study will provide clinical evidence for the application of dual orexin receptor antagonists in the treatment of Parkinson's Disease.",[25,414,415],"Insomnia","Motor Disorder",[25,417,418,414,415],"Lemborexant","orexin receptor antagonist",{"date":325,"type":40},{"date":397,"type":21},{"date":422,"type":21},"2026-12-01",{"name":401,"class":132},{"id":425,"slug":4,"hasResults":11,"nctId":426,"briefTitle":427,"officialTitle":428,"acronym":429,"eligibilityCriteria":430,"healthyVolunteers":55,"sex":16,"minAge":314,"maxAge":18,"enrollmentInfo":431,"targetDuration":433,"studyType":22,"phases":4,"briefSummary":434,"conditions":435,"keywords":437,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":445,"lastUpdatePostDateStruct":446,"startDateStruct":447,"completionDateStruct":449,"leadSponsor":451,"locationsCount":85},"100642000","NCT07644013","Prospective Multicenter Registry Study of Multiple System Atrophy in China","Clinical Features and Natural History of Multiple System Atrophy: A Prospective Multicenter Registry Study in China","MSA Registry S","Inclusion Criteria\n\n1. Patients with clinically established or clinically probable multiple system atrophy according to the 2022 Movement Disorder Society diagnostic criteria; or\n2. Patients with clinically established or clinically probable Parkinson disease according to the Movement Disorder Society diagnostic criteria; or\n3. Healthy controls or controls without hereditary or neurodegenerative diseases who voluntarily agree to participate.\n4. Age between 40 and 75 years.\n5. Ability to provide informed consent or availability of a legally authorized representative when applicable.\n\nExclusion Criteria\n\n1. Parkinsonism that cannot be classified as Parkinson disease or multiple system atrophy at the time of evaluation.\n2. Clinical suspicion or diagnosis of other atypical parkinsonian syndromes, including progressive supranuclear palsy, dementia with Lewy bodies, or corticobasal syndrome.\n3. Secondary parkinsonism due to intracranial space-occupying lesions, normal pressure hydrocephalus, drug-induced parkinsonism, or other identifiable causes.\n4. Comorbid diseases that may substantially affect autonomic function, such as diabetic peripheral neuropathy or amyloidosis.\n5. Refusal to participate in the study or refusal to undergo routine clinical evaluations for parkinsonian syndromes.\n6. Psychiatric or behavioral abnormalities that preclude reliable clinical data collection or scale-based assessment.",{"count":432,"type":21},214,"6 Months","Multiple system atrophy is a rare, rapidly progressive neurodegenerative disease characterized by variable combinations of parkinsonism, cerebellar ataxia, and autonomic dysfunction. Existing natural history studies from North America, Europe, and Japan suggest that clinical phenotypes and disease progression may differ across populations. However, comprehensive multicenter prospective data from Chinese patients with multiple system atrophy remain limited.\n\nThis prospective multicenter registry study aims to describe the clinical characteristics, longitudinal progression, and outcomes of Chinese patients with multiple system atrophy, to identify factors associated with disease progression and prognosis, and to establish a longitudinal cohort for future biomarker validation and clinical trial design.",[169,25,436],"Atypical Parkinsonism",[438,439,440,441,442,443,444,198],"Multiple system atrophy","natural history","prospective cohort","multicenter registry","disease progression","neuroimaging","biomarkers","2026-06-08",{"date":301,"type":40},{"date":448,"type":40},"2025-06-01",{"date":450,"type":21},"2030-06-30",{"name":182,"class":132},{"id":453,"slug":4,"hasResults":11,"nctId":454,"briefTitle":455,"officialTitle":456,"acronym":4,"eligibilityCriteria":457,"healthyVolunteers":11,"sex":16,"minAge":92,"maxAge":4,"enrollmentInfo":458,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":460,"conditions":461,"keywords":4,"overallStatus":324,"whyStopped":4,"lastUpdateSubmitDate":462,"lastUpdatePostDateStruct":463,"startDateStruct":464,"completionDateStruct":465,"leadSponsor":467,"locationsCount":4},"100643825","NCT07622303","Depression, Anxiety and Sleep in Parkinson's Disease","Assessment of Depression , Anxiety and Sleep Disorders in Patients With Idiopathic Parkinson's Disease","A-Inclusion Criteria:\n\n1. Patients diagnosed with idiopathic Parkinson's disease according to the Movement Disorder Society Clinical Diagnostic Criteria for Parkinson's Disease (Postuma et al., 2015).\n2. Age ≥ 50 years.\n3. Ability to understand and respond to questionnaires and rating scales.\n4. Ability and willingness to provide informed consent.\n\nB-Exclusion Criteria:\n\n1. Patients with atypical parkinsonism.\n2. Patients with a history of other major neurological disorders (e.g., stroke, Alzheimer's disease, multiple sclerosis).\n3. Patients with severe cognitive impairment or dementia that prevents reliable completion of rating scales.\n4. Patients with a current diagnosis of severe psychiatric disorders unrelated to 5-Parkinson's disease (e.g., schizophrenia, bipolar disorder).\n\n6-Patients with unstable medical conditions. 7-Patients unable or unwilling to provide informed consent.",{"count":459,"type":21},100,"This study aims to assess the prevalence and severity of depression, anxiety, and sleep disorders among patients with idiopathic Parkinson's disease. The study will evaluate the relationship between neuropsychiatric symptoms and disease characteristics in order to improve early recognition and patient quality of life.",[25],"2026-06-05",{"date":394,"type":40},{"date":355,"type":21},{"date":466,"type":21},"2027-05-31",{"name":468,"class":132},"Sohag University",{"id":470,"slug":4,"hasResults":11,"nctId":471,"briefTitle":472,"officialTitle":472,"acronym":4,"eligibilityCriteria":473,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":57,"enrollmentInfo":474,"targetDuration":4,"studyType":60,"phases":476,"briefSummary":477,"conditions":478,"keywords":480,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":482,"lastUpdatePostDateStruct":483,"startDateStruct":484,"completionDateStruct":486,"leadSponsor":488,"locationsCount":85},"100177251","NCT01581580","Deep Brain Stimulation Surgery for Movement Disorders","* INCLUSION CRITERIA:\n\nTo be eligible for entry into the study, candidates must meet all the following criteria:\n\nBe 18 years of age or older.\n\nAble to provide informed consent.\n\nHave a clinical diagnosis of one of the following as confirmed by the NIH movement disorders clinic team and the multi-disciplinary DBS surgical conference, and deemed as appropriate for the use of Deep Brain Stimulation therapy:\n\n* idiopathic PD not adequately controlled with medication or\n* primary dystonia that is medically refractory, or\n* ET that is not adequately controlled by medications or constitutes a significant functional disability.\n\nEXCLUSION CRITERIA:\n\nCandidates will be excluded if they:\n\nAre unable or unwilling to give informed consent to the research procedures.",{"count":475,"type":21},200,[141],"Background:\n\n\\- Deep brain stimulation (DBS) is an approved surgery for certain movement disorders, like Parkinson's disease, that do not respond well to other treatments. DBS uses a battery-powered device called a neurostimulator (like a pacemaker) that is placed under the skin in the chest. It is used to stimulate the areas of the brain that affect movement. Stimulating these areas helps to block the nerve signals that cause abnormal movements. Researchers also want to record the brain function of people with movement disorders during the surgery.\n\nObjectives:\n\n* To study how DBS surgery affects Parkinson s disease, dystonia, and tremor.\n* To obtain information on brain and nerve cell function during DBS surgery.\n\nEligibility:\n\n\\- People at least 18 years of age who have movement disorders, like Parkinson's disease, essential tremor, and dystonia.\n\nDesign:\n\n* Researchers will screen patients with physical and neurological exams to decide whether they can have the surgery. Patients will also have a medical history, blood tests, imaging studies, and other tests. Before the surgery, participants will practice movement and memory tests.\n* During surgery, the stimulator will be placed to provide the right amount of stimulation for the brain. Patients will perform the movement and memory tests that they practiced earlier.\n* After surgery, participants will recover in the hospital. They will have a followup visit within 4 weeks to turn on and adjust the stimulator. The stimulator has to be programmed and adjusted over weeks to months to find the best settings.\n* Participants will return for followup visits at 1, 2, and 3 months after surgery. Researchers will test their movement, memory, and general quality of life. Each visit will last about 2 hours.",[25,147,479],"Dystonia",[25,145,481,262,479,98,147],"Neurophysiology","2026-06-04",{"date":462,"type":40},{"date":485,"type":40},"2011-08-17",{"date":487,"type":21},"2029-12-01",{"name":157,"class":84},{"id":490,"slug":4,"hasResults":11,"nctId":491,"briefTitle":492,"officialTitle":493,"acronym":494,"eligibilityCriteria":495,"healthyVolunteers":11,"sex":16,"minAge":92,"maxAge":118,"enrollmentInfo":496,"targetDuration":4,"studyType":60,"phases":498,"briefSummary":500,"conditions":501,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":502,"lastUpdatePostDateStruct":503,"startDateStruct":504,"completionDateStruct":506,"leadSponsor":508,"locationsCount":510},"100606342","NCT07174310","A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease","A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early-Stage Parkinson's Disease","PARAISO","Inclusion Criteria:\n\n* Body weight within 40-110 kilograms (kg) (88-242 pounds \\[lbs\\]) and a body mass index within the range 18-34 kg\u002Fm2\n* Diagnosis of idiopathic PD based on Movement Disorder Society (MDS) criteria\n* Has received monotherapy treatment\n* An MDS-UPDRS Part IV score of 0 at screening and prior to randomization\n* Hoehn and Yahr (H\\&Y) Stage 1 or 2 off medication at screening and prior to randomization\n* Agreement to adhere to the contraception requirements\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding, or intention of becoming pregnant during the study or within the time frame in which contraception is required\n* Medical history indicating a parkinsonian syndrome other than idiopathic PD\n* Diagnosis of a significant neurologic disease other than PD\n* Chronic uncontrolled hypertension",{"count":497,"type":21},900,[499],"PHASE3","The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of prasinezumab compared with placebo in participants with early-stage Parkinson's disease (PD) on stable symptomatic monotherapy with levodopa.",[25],"2026-06-03",{"date":482,"type":40},{"date":505,"type":40},"2025-11-24",{"date":507,"type":21},"2031-06-30",{"name":509,"class":47},"Hoffmann-La Roche",160,{"id":512,"slug":4,"hasResults":11,"nctId":513,"briefTitle":514,"officialTitle":515,"acronym":4,"eligibilityCriteria":516,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":4,"enrollmentInfo":517,"targetDuration":4,"studyType":60,"phases":518,"briefSummary":519,"conditions":520,"keywords":526,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":529,"lastUpdatePostDateStruct":530,"startDateStruct":531,"completionDateStruct":533,"leadSponsor":535,"locationsCount":85},"100579202","NCT06821230","Dyadic Mindfulness for People With Parkinson's Disease and Their Caregivers","Enhancing Psychological Wellbeing and the Patient-caregiver Relationship Through Dyadic Mindfulness: A Randomized Controlled Trial in People With Parkinson's Disease and Their Caregivers","Inclusion Criteria of PwPD:\n\n* Chinese patients with idiopathic mild-moderate PD (as indicated by the Hoehn and Yahr Scale stages I-III: those with unilateral\u002Fbilateral symptoms, with\u002Fwithout postural instability who are able to walk\u002Fstand unassisted)\n* Aged ≥18 years\n\nInclusion Criteria of caregivers of PwPD:\n\n\\- Self-identified as the primary caregivers of their patient\n\nEither patient or caregiver needs to experience at least mild negative emotions (as indicated by the 21-item Depression, Anxiety and Stress Scale \\[DASS21\\] score of Depression subscale ≥10, Anxiety subscale ≥8, or Stress subscale ≥15)\n\nBoth need to be able to communicate in Cantonese and provide written consent.\n\nExclusion Criteria:\n\n* Engage in regular supervised mind-body practices such as Tai Chi, yoga, or other forms of mindfulness training (\\>2 times per week)\n* Have a pre-existing acute psychotic disease\n* Currently participating in any other behavioral or pharmacological trial\n* Have significant cognitive impairment, as indicated by an Abbreviated Mental Test score≤ 6\n* Have other contraindications that may limit their full participation (e.g., severe hearing\u002Fvision impairment)",{"count":475,"type":21},[141],"The proposed two-arm randomized waitlist-controlled trial will use a mixed-methods design to investigate the effects of dyadic mindfulness on physio-psycho-spiritual outcomes in people with Parkinson's Disease (PwPD) and their family caregivers. One hundred Chinese patient-caregiver dyads will be randomized to receive eight weekly 90-minute dyadic mindfulness sessions or usual care. Outcome measures include negative emotions (primary outcome), patient-caregiver relationship, mindfulness, HRQOL, gut microbiome, PD-related symptoms, and caregiving burden. An actor-partner interdependence model will be used to explore the interactions of treatment effects within the dyads. The dyads will be assessed at baseline(T0), post-intervention(T1), and 4-months post-intervention(T2). The investigators will also invite 25 dyads to attend in-depth interviews exploring their experiences, perceived changes, and factors attributable to the effectiveness\u002Fineffectiveness of the intervention. Generalized linear mixed-effects (GLME) with intention-to-treat analysis will be used to compare the changes in outcomes over time within and between the two arms. The findings will be triangulated to provide a comprehensive evaluation of the intervention's effectiveness. This study will generate rigorous scientific evidence to inform the application of dyadic mindfulness as a public health practice preventing the progression of psychological distress in PwPD and caregivers to clinically severe levels. Its self-help nature also enriches the primary care for this clinical cohort.",[521,522,146,523,524,525,240],"Mindfulness","Caregivers","Neurodegenerative Disease","Dyadic Intervention","Psychosocial Health",[527,521,528],"Parkinsons disease","dyadic care","2026-05-28",{"date":355,"type":40},{"date":532,"type":40},"2025-02-11",{"date":534,"type":21},"2027-06-30",{"name":536,"class":132},"The University of Hong Kong",{"id":538,"slug":4,"hasResults":11,"nctId":539,"briefTitle":540,"officialTitle":541,"acronym":4,"eligibilityCriteria":542,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":543,"enrollmentInfo":544,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":546,"conditions":547,"keywords":548,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":550,"lastUpdatePostDateStruct":551,"startDateStruct":552,"completionDateStruct":554,"leadSponsor":556,"locationsCount":557},"100586525","NCT06916507","Study to Assess Real Life Effectiveness of Foslevodopa\u002FFoscarbidopa in Adult German Participants at Initial Stages of Advanced Parkinson's Disease (EARLY-FOS)","German Real-World Evidence Study on the Effectiveness of Foslevodopa\u002FFoscarbidopa at Initial Stages of Advanced Parkinson's Disease: Motor Symptoms, Quality of Life, Psychosocial Functioning and Work Ability","Inclusion Criteria:\n\n* Participants with a diagnosis of levodopa-responsive idiopathic Parkinson's disease\n* Eligibility for foscarbidopa\u002Ffoslevodopa (LDp\u002FCDp) therapy in accordance with the approved local label\n* Participant must be an adult male or female, 18-64 years of age\n* Time since beginning of motor fluctuations ≤ 3 years\n* The Hoehn and Yahr (H\\&Y) stage \\\u003C 3 in the on-medication condition\n* Decision to treat with LDp\u002FCDp made by the clinician prior to any decision to approach the participant to participate in this study\n\nExclusion Criteria:\n\n* Previous Exposure to any device-aided therapy (DAT).\n* Any condition included in the contraindications section of the approved local LDp\u002FCDp label.\n* Participants with Mini mental state examination (MMSE) score \\\u003C 24","64 Years",{"count":545,"type":21},125,"Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. This study will assess how effective foscarbidopa\u002F foslevodopa is in treating German adult participants at initial stages of advanced Parkinson's disease under routine clinical practice.\n\nFoslevodopa\u002FFoscarbidopa is an approved drug for the treatment of Parkinson's Disease. Approximately 125 adult participants who are prescribed Foslevodopa\u002FFoscarbidopa by their doctors will be enrolled across approximately 20 sites in Germany.\n\nParticipants will receive Foslevodopa\u002FFoscarbidopa subcutaneous infusion as prescribed by their physician. Participants will be followed for up to 12 months.\n\nThere is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.",[25],[25,549],"Foscarbidopa\u002FFoslevodopa","2026-05-26",{"date":529,"type":40},{"date":553,"type":40},"2025-05-06",{"date":555,"type":21},"2027-09",{"name":294,"class":47},17,{"id":559,"slug":4,"hasResults":11,"nctId":560,"briefTitle":561,"officialTitle":562,"acronym":563,"eligibilityCriteria":564,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":4,"enrollmentInfo":565,"targetDuration":4,"studyType":60,"phases":567,"briefSummary":568,"conditions":569,"keywords":571,"overallStatus":324,"whyStopped":4,"lastUpdateSubmitDate":576,"lastUpdatePostDateStruct":577,"startDateStruct":578,"completionDateStruct":579,"leadSponsor":581,"locationsCount":85},"100640118","NCT07611578","Dual Tasking Training to Enhance Self-Efficacy in Individuals With Parkinson's Disease","Enhancing Self-Efficacy in Individuals With Parkinson's Disease Through Dual Task Training: Effects of Task Modality, Attentional Prioritization, and Cognitive Status","DEEP-PD","Participants diagnosed with idiopathic Parkinson's disease confirmed by a neurologist will be recruited in this study. Inclusion criteria will be:\n\n1. Hoehn \\& Yahr stages I, II or III\n2. Participants with no or mild to moderate neurocognitive impairments\n3. Participants with and without symptoms of depression\n4. Able to walk independently\n5. Unaltered dose and type of medication up to three months before the commencement of the study\n6. Participants able to understand and respond to the instructions given in the study.\n\nExclusion criteria will be:\n\n1. The presence of any other concomitant neurological, musculoskeletal disease\n2. History of leg or brain trauma or surgery\n3. Vision or hearing problems that may affect the performance of cognitive tests\n4. Clinical diagnosis of major neurocognitive disorder",{"count":566,"type":21},112,[141],"Parkinson's disease (PD) is a neurodegenerative disorder characterized by motor and cognitive impairments that substantially reduce functional independence, social participation, and quality of life. A key psychosocial factor affected by these impairments is self-efficacy, defined as an individual's belief in their ability to successfully perform tasks and achieve personal goals. In people with PD, reduced self-efficacy is closely associated with motor dysfunction, cognitive decline, fear of falling, depressive symptoms, and decreased motivation for physical and social activities. These factors interact in a bidirectional manner, creating a negative cycle in which poor confidence limits participation, further accelerating functional deterioration.\n\nFrom a neurophysiological perspective, the degeneration of dopaminergic neurons in PD disrupts the automatic control of movement. As a consequence, individuals with PD rely more heavily on cognitive and attentional resources to execute daily motor activities. This reliance becomes particularly problematic in dual-tasking situations, where two tasks must be performed simultaneously, such as a motor task combined with a cognitive task or two concurrent motor tasks. Because attentional capacity is limited, dividing attention across tasks frequently results in performance declines in one or both tasks, a phenomenon referred to as dual-task interference or dual-task cost. Low confidence when facing these situations may reinforce avoidance behaviors, thereby further diminishing physical activity and community engagement.\n\nDual-task training has been proposed as a rehabilitation strategy to improve functional performance, self-efficacy, and daily functioning in people with PD. However, important gaps remain in the evidence. It is currently unclear whether motor-cognitive or motor-motor dual-task training is more effective, particularly when considering the presence or absence of cognitive impairment. Additionally, the relative impact of secondary cognitive versus secondary motor tasks on primary motor task performance has not been well established. Another unresolved issue concerns attentional prioritization strategies during dual-task training. Fixed-priority strategies require individuals to attend equally to both tasks, whereas variable-priority strategies involve alternating attention between tasks. The optimal strategy for individuals with PD, especially those with cognitive deficits, remains unknown.\n\nThe proposed research aims to address these knowledge gaps by systematically evaluating the effects of different dual-task training modalities and attentional prioritization strategies on self-efficacy, functional performance, and quality of life in individuals with PD, both with and without cognitive impairment. An additional objective is to investigate whether improvements in dual-task performance are associated with reduced attentional demands, as reflected by decreased activity in the prefrontal cortex, which is considered a key neural marker of cognitive load during task performance.\n\nThe research program comprises two complementary studies. Study 1 is a randomized clinical trial with a factorial design stratified by cognitive status. Participants with PD are randomly assigned to one of four intervention groups combining dual-task modality (motor-cognitive or motor-motor) with attentional strategy (fixed-priority or variable-priority). All participants undergo baseline assessments conducted by an interdisciplinary team and complete 24 individualized training sessions over an eight-week period. Outcome measures include self-efficacy, motor and cognitive performance, quality of life, dual-task cost, and prefrontal cortex activity. Study 2 uses a cross-sectional design that includes individuals with PD from study 1 and a matched group of healthy older adults. Using identical assessment procedures, this study compares dual-task interference and prefrontal cortex activity between people with PD and healthy controls, providing additional insight into disease-specific cognitive-motor interactions. Overall, this research seeks to inform evidence-based, personalized rehabilitation strategies by identifying the most effective dual-task training approaches for improving confidence, functional ability, and quality of life in individuals with PD.",[570],"Parkinson´s Disease",[572,573,574,575],"dual tasking","motor cognitive training","cognitive function","self efficacy","2026-05-22",{"date":529,"type":40},{"date":355,"type":21},{"date":580,"type":21},"2029-01-31",{"name":582,"class":132},"Alvaro Reyes",{"id":584,"slug":4,"hasResults":11,"nctId":585,"briefTitle":586,"officialTitle":587,"acronym":588,"eligibilityCriteria":589,"healthyVolunteers":55,"sex":16,"minAge":117,"maxAge":93,"enrollmentInfo":590,"targetDuration":4,"studyType":60,"phases":592,"briefSummary":593,"conditions":594,"keywords":595,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":597,"lastUpdatePostDateStruct":598,"startDateStruct":600,"completionDateStruct":602,"leadSponsor":604,"locationsCount":606},"100559520","NCT06565195","A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's Disease","A Randomized, Double-blind (Sponsor-unblinded), Placebo-controlled, Single-ascending-dose Study in Healthy Volunteers and a Double-blind (Sponsor-unblinded), Placebo-controlled, Multiple-ascending-dose Study in Patients With Parkinson's Disease to Evaluate the Safety, Tolerability, and PK\u002FPD of LY3962681","PROSPECT-PD","Inclusion Criteria:\n\n* Participant is overtly healthy as determined by medical evaluation. Rescreening is allowed in this study.\n* A Montreal Cognitive Assessment score greater than or equal to 24.\n* Stable use of background medications at least 8 weeks prior to IP administration, including but not limited to those used for treatment of Parkinson's disease (including deep brain stimulation), and the investigator must expect that participant can tolerate a minimum of 6 months without dose adjustment.\n\nMAD study only\n\n* Participant has a diagnosis of Parkinson's disease per UK Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria.\n* Modified Hoehn and Yahr Stage 1 to 2.5 in the practically defined OFF state.\n* A positive result on CSF alpha-synuclein Seed Amplification Assay. (A prior positive result \\[within 1 year of screening\\] accepted with sponsor approval if patient did not participate in another Parkinson's disease clinical trial during this period.) (US and Japan only)\n* UPSIT score of 20 percentile or less, corrected for age and sex (EU and UK only).\n* An abnormal DaT-SPECT consistent with parkinsonism. (History of an abnormal DaTSPECT with the report confirmed by study investigator will be accepted.)\n* For participants not taking Parkinson's disease medications, not expected to initiate treatment within 6 months.\n* Have a body weight within 40 kg (88 pounds) to 110 kg (242 pounds), inclusive, and body mass index within the range of 17 to 34 kg\u002Fm\\^2, inclusive.\n\nExclusion Criteria:\n\n* MAD study only: Significant neurological disease affecting the central nervous system other than Parkinson's disease that may be a cause for the participant's clinical symptoms or may confound study objectives.\n* Current concomitant disease or serious or unstable illnesses, including central nervous system (SAD study only), cardiovascular, hepatic, renal, gastroenterology, respiratory, endocrinologic, neurologic (MAD study only: other than Parkinson's disease), psychiatric, immunologic, or hematologic disease and other conditions that, in the investigator's opinion, could interfere with the conduct of the study or that would, in the opinion of the investigator, pose an unacceptable safety risk to the participant.\n* Participant is generally frail or has any medical disorders that, in the opinion of the investigator, could interfere with study-related procedures (including safe performance of IT injection or LP), such as prohibitive spinal diseases, bleeding diathesis, clinically significant coagulopathy, thrombocytopenia, or increased intracranial pressure.\n* Have a 12-lead ECG abnormality at screening that, in the opinion of the investigator, increases the risks associated with participating in the study or may confound ECG data analysis.\n* MAD study only: Treatment with continuous intestinal delivery Parkinson's disease medication (for example, Duodopa).\n* MAD study only: Significant renal impairment (estimated glomerular filtration rate \\[eGFR\\] \\\u003C45 mL\u002Fmin\u002F1.73 m\\^2).\n\nOther protocol-defined inclusion\u002Fexclusion criteria may apply.",{"count":591,"type":21},124,[62],"The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics\u002Fpharmacodynamics (PK\u002FPD) of LY3962681 in healthy volunteers and patients with Parkinson's disease.\n\nThe study consists of two parts, the Single Ascending Dose (SAD) study and the Multiple Ascending Dose (MAD) study.\n\nDuring the SAD portion of the study, healthy volunteers will receive a single dose of LY3962681 or placebo (artificial cerebrospinal fluid \\[aCSF\\]) administered intrathecally (into the spinal fluid). During the MAD portion of the study, patients with Parkinson's disease will receive two doses of either LY3962681 or placebo (aCSF) administered intrathecally (into the spinal fluid), 12 to 24 weeks apart.\n\n* The treatment period in the SAD study will be 1 day. The treatment period in the MAD study will be 2 dosing days, 12 to 24 weeks apart.\n* The follow-up period in the SAD study will be up to 52 weeks. The follow-up period in the MAD study will be up to 52 weeks after Dose 2.",[25],[28,596],"Healthy volunteers","2026-05-14",{"date":599,"type":40},"2026-05-18",{"date":601,"type":40},"2024-08-27",{"date":603,"type":21},"2029-05-05",{"name":605,"class":47},"Prevail Therapeutics",4,""]